It would be of great interest to examine the differential expression of the two isoforms in inflammed tissues and peripheral blood from patients with asthma, chronic obstructive pulmonary disease (COPD), EoE, allergic rhinitis, etc. Because of the pathophysiological relevance of long TSLP expression in all these diseases, the cytokine has been repeatedly suggested as a valid target for therapy with antibodies that would target TSLP and/or prevent its binding to TSLPR (42–45). This evidence concerns the gene TSLP and chronic obstructive pulmonary disease.